Stuart L. Goldberg, MD, On the Role of the Multidisciplinary Approach in Biomarker Testing

Article

The expert spoke about the importance of coordination to make sure every person involved with a patient’s care is in agreement as to how to treat the patient most effectively.

Stuart L. Goldberg, MD, from Hackensack University Medical Center, spoke with CancerNetwork® about the role that the multidisciplinary approach plays in biomarker testing and the importance of coordination in this setting. 

Transcription:

In order to do biomarkers, you have to coordinate and get the sample properly. Many of our patients with colon cancer, with lung cancer, they’re not seeing the oncologist first. The biopsies are being done by the pulmonologists, by the gastroenterologist, and those samples may then go to a pathologist who doesn’t think about the diagnosis, or if they get the diagnosis, they then fail to then talk to the oncologist early and send the samples off. And so, we need to coordinate between the primary care physician, the person who’s making the diagnosis at the tissue level, the pathologist who gets that sample, and the oncologist to make sure that everyone’s on the same page as to what type of genetic profiling needs to be done and how to do it in a cost effective manner. We don’t need to spend lots of money on tests that we’re not going to be doing if the patient’s not going to be getting therapy. But on the other hand, if the patient is going to be getting therapy, we want to make sure that all the right tests are being done. 

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Related Content